Ticker > Company >

Cipla share price

Cipla Ltd.

NSE: CIPLA BSE: 500087 SECTOR: Pharmaceuticals & Drugs  5.86 L   3.75 K   670

1318.80
-1.55 (-0.12%)
BSE: Today, 11:34 AM

Price Summary

Today's High

₹ 1325

Today's Low

₹ 1315.15

52 Week High

₹ 1672.2

52 Week Low

₹ 1283

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

106530.12 Cr.

Enterprise Value

106251.67 Cr.

No. of Shares

80.78 Cr.

P/E

23.08

P/B

3.15

Face Value

₹ 2

Div. Yield

1.21 %

Book Value (TTM)

₹  419.2

CASH

278.45 Cr.

DEBT

0 Cr.

Promoter Holding

29.21 %

EPS (TTM)

₹  57.14

Sales Growth

14.91%

ROE

17.2 %

ROCE

21.59%

Profit Growth

38.86 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Cipla Ltd.

Paracip Montair LC Cipmolnu Dytor Moxicip Novamox Lametec Ibugesic Fourderm CPink CDense Productiv nicotex ActivKids immuno boosters cofsils CIPHANDS OMNIGEL CORYX BRONCOL COUGH SYRUP Cheston Asthalin Norflox Urimax CIPREMI Aerocort Budecort Duolin Foracort Seroflo Amlopres Atorlip Ciplar Cresar Clopivas Azee Imatib Kelfer Lamivir Tenvir Ibugesic Plus Omnigel Norflox-TZ Unobiotics Cipladine Clocip Maxirich Prolyte ORS MamaXpert Ciphands

Index Presence

The company is present in 48Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.91%
3 Year7.38%
5 Year8.51%

Profit Growth

1 Year26.5%
3 Year20.36%
5 Year17.34%

ROE%

1 Year17.2%
3 Year13.48%
5 Year13.01%

ROCE %

1 Year21.59%
3 Year17.77%
5 Year17.3%

Debt/Equity

0

Price to Cash Flow

32.27

Interest Cover Ratio

429.1152

CFO/PAT (5 Yr. Avg.)

1.02216754175623

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2025 29.21 0.00
Sep 2025 29.21 0.00
Jun 2025 29.19 0.00
Mar 2025 29.20 0.00
Dec 2024 29.19 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.4013453227949% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 429.1152.
  • The Company has been maintaining an effective average operating margins of 24.9593412942778% in the last 5 years.
  • Company’s PEG ratio is 0.594500323648672.
  • The company has an efficient Cash Conversion Cycle of -36.3235 days.
  • Company has a healthy liquidity position with current ratio of 5.7703.
  • The company has a good cash flow management; CFO/PAT stands at 1.02216754175623.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.0951793870697.

 Limitations

  • The company has shown a poor revenue growth of 7.38222033324927% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 4970.88 4797.89 5046.17 5225.72 4498.08
Total Expenditure 3309.05 3479.18 3421.72 3703.09 3776.88
Operating Profit 1661.83 1318.71 1624.45 1522.63 721.2
Other Income 188.69 293.37 271.07 254.66 416.7
Interest 3.55 3.49 5.88 2.65 4.03
Depreciation 142.62 147.7 145.69 141.3 153.33
Exceptional Items 0 294.66 0 0 -244.37
Profit Before Tax 1704.35 1755.55 1743.95 1633.34 736.17
Tax 266.2 270.15 440.82 422.81 119.29
Profit After Tax 1438.15 1485.4 1303.13 1210.53 616.88
Adjusted EPS (Rs) 17.81 18.39 16.13 14.99 7.64

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 11302.71 15380.82 14345.34 16574.34 19044.85
Total Expenditure 8235.3 11669.59 11000.23 12090.19 13268.3
Operating Profit 3067.41 3711.23 3345.11 4484.15 5776.55
Other Income 230.28 666.7 464.57 1070.66 986.61
Interest 45.07 26.93 22.27 20.25 15.11
Depreciation 468.62 546.62 595.91 587.59 573.89
Exceptional Items 0 0 -185.9 0 294.66
Profit Before Tax 2784 3804.38 3005.6 4946.97 6468.82
Tax 739.35 921.8 861.54 1232.78 1311.17
Net Profit 2468.28 2957.93 2513.47 4077.25 5157.65
Adjusted EPS (Rs.) 25.35 35.73 26.56 46 63.86

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 161.29 161.36 161.43 161.47 161.52
Total Reserves 19766.27 22352.19 24476.66 27812.45 31937.72
Borrowings 0 0 0 0 0
Other N/C liabilities 344.24 276.16 258.64 217.06 263.18
Current liabilities 2691.94 2632.37 2699.74 2862.25 3183.42
Total Liabilities 22963.74 25449.05 27596.47 31053.23 35545.84
Assets
Net Block 3942.66 3846.57 3747.28 3603.14 3764.76
Capital WIP 275.04 186.26 441.53 580.9 523.11
Intangible WIP 80.07 81.42 62.72 89.37 115.29
Investments 7720.99 8934.88 9137.91 9410.17 10501.68
Loans & Advances 596.1 555.68 748.77 1904.67 1915.8
Other N/C Assets 158.13 509.2 87.13 607.14 355.98
Current Assets 10190.75 11335.04 13371.13 14857.84 18369.22
Total Assets 22963.74 25449.05 27596.47 31053.23 35545.84
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 3350.66 3905.08 3685.17 5432.14 6174.16
Adjustment 520.41 73.26 269.57 -342.91 -285.65
Changes in Assets & Liabilities 541.19 -270.88 164.57 -138.3 -1229.16
Tax Paid -951.95 -934.03 -1084.26 -1224.16 -1358.36
Operating Cash Flow 3460.31 2773.43 3035.05 3726.77 3300.99
Investing Cash Flow -3361.33 -2464.14 -2758.09 -2882.9 -2308.84
Financing Cash Flow -65.8 -426.72 -424.77 -708.83 -1073.93
Net Cash Flow 33.18 -117.43 -147.81 135.04 -81.78

Corporate Actions

Investors Details

PARTICULARS Dec 2024% Mar 2025% Jun 2025% Sep 2025% Dec 2025%
promoters 29.19 29.20 29.19 29.21 29.21
kamil hamied 1.36 1.36 1.36 1.36 1.36
m k hamied 3.45 3.46 3.45 3.46 3.46
sophie ahmed 5.70 5.71 5.71 5.71 5.71
yusuf khwaja hamied - - 18.68 18.69 18.69
yusuf khwaja hameid 18.67 18.68 - - -
PARTICULARS Dec 2024% Mar 2025% Jun 2025% Sep 2025% Dec 2025%
investors 70.81 70.80 70.81 70.79 70.79
dsp msci india etf - - - - 1.56
government pension fund g... 2.69 2.53 2.33 1.98 1.84
hdfc mutual fund-hdfc arb... - - 5.21 - 4.70
icici prudential nifty 50... - - 1.57 - 1.88
investor education and pr... - - 0.32 - 0.32
lici asm non par - - - 6.15 7.71
nippon life india trustee... - - - - 1.59
nps trust a/c uti pension... - - 1.41 - 1.51
parag parikh flexi cap fu... - - - 1.30 1.43
sbi arbitrage opportuniti... - - 3.02 - 3.46
vanguard total internatio... - 1.00 1.00 1.01 1.01
dsp regular savings fund - - - 1.97 -
franklin india arbitrage ... - - - 1.02 -
hdfc mutual fund - hdfc m... 5.11 - - 5.19 -
icici prudential nifty he... - - - 1.50 -
investor education and pr... 0.32 0.32 - 0.32 -
nippon life india trustee... - - - 1.53 -
nps trust a/c - lic pensi... - - - 1.35 -
sbi balanced advantage fu... - - - 3.40 -
uti nifty 50 index fund - - - 1.05 -
axis nifty 50 etf - - 1.05 - -
dsp multicap fund 1.76 - 1.92 - -
lici index plus flexi sma... - - 4.76 - -
parag parikh arbitrage fu... - 1.02 1.19 - -
uti nifty india manufactu... - - 1.05 - -
axis mutual fund trustee ... - 1.14 - - -
dsp healthcare fund - 1.90 - - -
hdfc large and mid cap fu... - 5.13 - - -
icici prudential bharat c... - 1.70 - - -
kotak mahindra trustee co... - 1.03 - - -
lici new pension plus sec... - 4.16 - - -
nps trust -a/c lic pensio... - 1.15 - - -
sbi long term equity fund... 2.85 2.79 - - -
uti conservative hybrid f... - 1.06 - - -
aditya birla sun life tru... 1.02 - - - -
axis elss tax saver fund 1.17 - - - -
icici prudential nifty50 ... 1.80 - - - -
kotak mahindra trustee co... 1.17 - - - -
lic 3.41 - - - -
nps 1.45 - - - -
uti elss tax saver fund 1.07 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE RATINGS
Credit CARE
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research Ventura
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Edelweiss
Research BOB Capital Markets Ltd.
Research SMC online

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q3FY22
Concall Q3FY21
Concall Q3 FY20
Concall Q2FY24
Concall Q2FY21
Concall Q2FY20
Concall Q1FY26
Concall Q1FY24
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY21
Presentation Q3 FY20
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20

Company News

Cipla - Quaterly Results 24 Jan, 12:00 AM Cipla's consolidated net profit drops 57% in Q3 23 Jan, 4:58 PM Cipla inks pact with ImmunoACT to commercialize talicabtagene autoleucel in Africa 21 Jan, 2:59 PM Cipla launches orally inhaled insulin in India 23 Dec, 2:43 PM Cipla informs about updates 19 Dec, 12:02 PM Cipla moves up on launching ‘Yurpeak’ 11 Dec, 9:54 AM Cipla launches ‘Yurpeak’ 10 Dec, 5:25 PM Cipla gains on completing acquisition of 100% stake in Inzpera Healthsciences 5 Dec, 2:35 PM Cipla completes acquisition of 100% stake in Inzpera Healthsciences 5 Dec, 12:23 PM Cipla gains on launching therapy for Knee Osteoarthritis ‘Ciplostem’ 4 Dec, 12:03 PM Cipla launches therapy for Knee Osteoarthritis ‘Ciplostem’ 4 Dec, 10:49 AM Cipla launches integrated lung diagnostics, wellness centre in Delhi 29 Nov, 11:26 AM Cipla to acquire Inzpera Healthsciences 4 Nov, 3:41 PM Cipla - Quaterly Results 31 Oct, 12:00 AM Cipla informs about financial results 30 Oct, 5:10 PM Cipla reports 4% rise in Q2 consolidated net profit 30 Oct, 3:51 PM Cipla enters into agreement with Eli Lilly and Company 23 Oct, 5:18 PM Cipla informs about product launch 23 Oct, 5:06 PM Cipla informs about revision in ESG rating 12 Sep, 5:31 PM Cipla’s arm recalling over 20,000 packs of Ibuterol Sulfate Inhalation Aerosol 28 Aug, 2:18 PM Cipla’s Bengaluru manufacturing facility classified as VAI by USFDA 5 Aug, 10:30 AM Cipla reports 10% rise in Q1 consolidated net profit 25 Jul, 5:22 PM Cipla - Quaterly Results 25 Jul, 1:19 PM Cipla - Quaterly Results 25 Jul, 1:19 PM Cipla - Quaterly Results 25 Jul, 1:19 PM Cipla signs definitive agreements for investment in iCaltech Innovations 22 Jul, 9:20 AM USFDA concludes cGMP inspection at Cipla’s Bengaluru manufacturing facility 31 May, 10:40 AM Cipla’s arm incorporates new wholly owned subsidiary in Germany 30 May, 4:14 PM Cipla’s arm acquires 26% stake in AMPIN Energy C&I Eighteen 30 May, 2:20 PM Cipla’s arm inks pact to acquire 26% stake in AMPIN Energy C&I Eighteen 20 May, 12:21 PM Cipla’s arm’s Mahape facility classified as VAI by USFDA 19 May, 10:30 AM Cipla reports 30% rise in Q4 consolidated net profit 13 May, 5:02 PM Cipla - Quaterly Results 13 May, 1:38 PM Cipla - Quaterly Results 13 May, 1:38 PM Cipla - Quaterly Results 13 May, 1:38 PM Cipla’s arm’s Goa facility classified as VAI by USFDA 21 Apr, 10:10 AM Cipla gets USFDA’s final approval for generic cancer drug 11 Apr, 9:23 AM Cipla informs about disclosure 11 Apr, 8:56 AM Cipla gets USFDA’s final nod for Nilotinib Capsules 21 Feb, 10:18 AM USFDA concludes cGMP inspection at analytical testing facility of Cipla’s arm 21 Feb, 10:07 AM Cipla informs about presentation for analyst 18 Feb, 12:15 PM USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated 10 Feb, 10:20 AM Cipla to invest in Cipla Medpro South Africa Proprietary 3 Feb, 5:23 PM Cipla informs about outcome of board meeting 28 Jan, 5:14 PM Cipla informs about outcome of board meeting 28 Jan, 4:57 PM Cipla reports 47% rise in Q3 consolidated net profit 28 Jan, 4:42 PM Cipla informs about press release 28 Jan, 3:14 PM Cipla informs about investor presentation 28 Jan, 3:09 PM Cipla - Quaterly Results 28 Jan, 2:00 PM Cipla - Quaterly Results 28 Jan, 2:00 PM

Cipla Stock Price Analysis and Quick Research Report. Is Cipla an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Cipla. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Cipla has a PE ratio of 23.0979901476108 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Cipla has ROA of 15.4887% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Cipla has a Current ratio of 5.7703.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Cipla has a ROE of 17.1986%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Cipla has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Cipla has reported revenue growth of 14.9056% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Cipla for the current financial year is 30.3312969122886%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Cipla is Rs 16 and the yield is 1.2118%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Cipla is Rs 57.1435. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Cipla in Ticker for free. Also, one can get the intrinsic value of Cipla by using Valuation Calculators, which are available with a Finology ONE subscription. 

Cipla FAQs

Q1. What is Cipla share price today?
Ans: The current share price of Cipla is Rs 1319.9.

Q2. What is the market capitalisation of Cipla?
Ans: Cipla has a market capitalisation of Rs 106618.97155723 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Cipla?
Ans: The PE ratio of Cipla is 23.0979901476108 and the P/B ratio of Cipla is 3.14867650145995, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Cipla share?
Ans: The 52-week high share price of Cipla is Rs 1673, and the 52-week low share price of Cipla is Rs 1281.7.

Q5. Does Cipla pay dividends?
Ans: Currently, Cipla pays dividends. Dividend yield of Cipla is around 1.2118%.

Q6. What are the face value and book value of Cipla shares?
Ans: The face value of Cipla shares is Rs 2, while the book value per share of Cipla is around Rs 419.192. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Cipla?
Ans: Cipla has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Cipla?
Ans: The ROE of Cipla is 17.1986% and ROCE of Cipla is 21.5868%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Cipla a good buy for the long term?
Ans: The Cipla long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Cipla undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Cipla appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Cipla’s financials?
Ans: You can review Cipla’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Cipla

Cipla Share Price, Stock Analysis & Company Profile

Welcome to the comprehensive stock analysis page for Cipla Ltd. Here, you can track the Cipla share price, analyse the company's financial health, and stay updated with the latest market news. Whether you are tracking the Cipla share price today for long-term investment or monitoring your portfolio, this page provides all the essential tools and reports for a detailed stock analysis.

About Cipla Ltd.

Cipla Ltd., established in 1935, is one of India’s most prominent and globally respected pharmaceutical companies. With a rich legacy spanning over eight decades, the company has transformed from a domestic manufacturer into a global healthcare leader. Cipla is renowned for its commitment to making medicines affordable and accessible, notably revolutionising HIV/AIDS treatment with its dollar-a-day "Triomune" therapy.

Headquartered in Mumbai, Cipla has a vast manufacturing footprint with 47 state-of-the-art facilities across the world. The company produces over 1,500 products in more than 50 dosage forms, catering to 80+ markets. It holds a leadership position in the respiratory segment and has a significant presence in urology, cardiology, and anti-infectives.

Business Model

Cipla operates on a diversified business model that balances stability with high-growth opportunities across geographies:

  1. One-India Strategy: India remains the company’s largest market, contributing significantly to its revenue through a mix of prescription drugs, branded generics, and its consumer healthcare business (Cipla Health). It leads in key therapeutic areas like respiratory and urology.

  2. North America Business: This vertical focuses on complex generics and value-added products, particularly in the respiratory and peptide segments. Products like Albuterol and Lanreotide have been key growth drivers in the US market.

  3. South Africa (SAGA): Cipla is one of the largest pharmaceutical players in South Africa, operating under the "One Africa" strategy. It focuses on private and tender markets, ensuring a steady stream of revenue from the continent.

  4. API and Emerging Markets: The company also manufactures Active Pharmaceutical Ingredients (APIs) for its own use and external sale, while expanding its footprint in emerging markets across Europe, Australia, and Latin America.

Listing Information

Cipla Ltd. is a blue-chip stock listed on India’s primary stock exchanges. Below are the static details regarding its listing, which serve as a permanent reference for investors.

  • Listing Year: 1995 (Listed on NSE/BSE)

  • Face Value: Rs 2 per share

  • ISIN: INE059A01026

  • Listing Exchanges: BSE and NSE

  • BSE Scrip Code: 500087

  • NSE Symbol: CIPLA

Investor Resources Available on This Page

We believe in empowering retail investors with professional-grade data. On this page, you can access a wealth of information to conduct your own Cipla stock analysis:

  • Interactive Price Chart: Analyse historical price movements and trends (data delayed by 15 minutes).

  • Company Ratios: Access a detailed table of key financial metrics such as PE ratio, ROE, and ROCE to evaluate valuation and efficiency.

  • Quarterly Results & Balance Sheet: Review the company’s latest quarterly earnings, profit and loss statements, and balance sheets to assess financial stability.

  • Cash Flow Analysis: Understand the company's liquidity position through detailed cash flow statements.

  • Shareholding Pattern: Check the latest ownership data, including promoter holdings and participation by FIIs and DIIs.

  • Annual Reports: Download official Annual Reports and investor presentations directly from the "Reports Section" on this page.

Frequently Asked Questions (FAQs)

Q1. What is the Cipla share price today?
The share price displayed at the top of this page reflects the latest trading value on the NSE and BSE. Please note that the price chart data is delayed by 15 minutes.

Q2. What are Cipla's main therapeutic areas?
Cipla is a global leader in respiratory medicines. It also has a strong portfolio in anti-retrovirals (HIV/AIDS), urology, cardiology, anti-infectives, and central nervous system (CNS) therapies.

Q3. Is Cipla a debt-free company?
Cipla maintains a very strong balance sheet with negligible debt. You can check the exact debt figures in the "Balance Sheet" or "Ratios" section on this page to confirm its current status.

Q4. Does Cipla pay dividends?
Yes, Cipla has a consistent track record of paying dividends to its shareholders. You can view the dividend yield and payout history in the "Corporate Actions" section.

Q5. Where is Cipla listed?
Cipla shares are traded on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

Q6. How can I download the Cipla Annual Report?
You can easily download the latest Annual Report and investor presentations from the "Documents" or "Reports Section" available on this page.

Q7. What is the face value of Cipla shares?
The face value of each equity share is Rs 2. This has been the face value since the company's stock split in the past.

Read More
X